Niacin for Pellagra and Skin Health

Table of Contents

1. The US South Pellagra Epidemic (1900-1940)
2. Corn, Nixtamalization, and the Bound-Niacin Problem
3. Joseph Goldberger's Epidemiologic Detective Work
4. The Four Ds — Dermatitis, Diarrhea, Dementia, Death
5. Casal's Necklace and the Pellagra Dermatitis Pattern
6. Hidden Modern Pellagra — Alcoholism, Crohn's, Hartnup
7. Secondary Pellagra — Carcinoid, Isoniazid, Human Immunodeficiency Virus
8. Topical Niacinamide for Acne and Barrier Function
9. Niacinamide for Hyperpigmentation
10. The ONTRAC Trial — Skin Cancer Chemoprevention
11. Niacinamide as a Skincare Ingredient (5-10%)
12. How Pellagra Is Treated
13. Cautions
14. Key Research Papers
15. Connections
16. Featured Videos

The US South Pellagra Epidemic (1900-1940)

Pellagra was first formally described in Spain by Gaspar Casal in 1735 (he called it "mal de la rosa" after the characteristic skin rash) and then in Italy in 1771 by Francesco Frapolli, who coined the name "pelle agra" — rough skin. For a century and a half, European pellagra remained largely confined to peasant populations in northern Italy and Spain dependent on corn-based polenta and tortas.

The American epidemic exploded between 1900 and 1940. By the 1910s pellagra was killing an estimated 6,000-7,000 Americans per year, with case counts in the tens of thousands. The geographic concentration was striking:

• South Carolina: over 30,000 cases reported in 1915 alone
• Mississippi, Alabama, Georgia, Tennessee: tens of thousands of cases through the 1920s-1930s
• Demographic concentration: impoverished tenant farmers, textile mill workers, prison populations, and orphanage residents — populations dependent on the "three M" diet of meal (cornmeal), meat (salt pork fat), and molasses
• Total US death toll: approximately 100,000 deaths from pellagra over the four decades of the epidemic, with many more suffering chronic disability

The cause was the rise of mechanized corn milling that removed the germ and bran, combined with the southern post-Reconstruction tenant-farming economy that left rural families dependent on cornmeal as the dominant staple. Unlike traditional Mesoamerican corn preparation (see next section), industrially milled American cornmeal was never alkali-treated — the niacin in the corn remained bound and biologically inaccessible.

Back to Table of Contents

Corn, Nixtamalization, and the Bound-Niacin Problem

Corn (maize) contains modest amounts of niacin — about 3.6 mg per 100 g of whole-grain yellow cornmeal and 1.0 mg per 100 g of degermed, unenriched yellow cornmeal (USDA FoodData Central) — but almost all of it is in a chemically bound form called niacytin, in which nicotinic acid is covalently linked to peptides and polysaccharides in the grain matrix. Niacytin is not hydrolyzed by digestive enzymes and is therefore biologically inaccessible. The "niacin content" measured by laboratory assay drastically overstates what the body can actually use.

The traditional Mesoamerican solution — developed independently by Maya, Aztec, and other indigenous cultures over thousands of years — is nixtamalization:

1. Dried corn kernels are soaked in an alkaline solution — traditionally lime water (calcium hydroxide, Ca(OH)₂) or wood ash lye, overnight or for several hours
2. The corn is rinsed and ground into masa for tortillas, tamales, atole, or pozole

The alkaline treatment hydrolyzes the niacytin peptide bonds and releases bioavailable free nicotinic acid. It also improves the calcium content (the lime provides calcium), improves amino acid balance (frees up bound tryptophan), and softens the corn kernels for grinding. Cultures that consumed nixtamalized corn — the Maya, the Aztec, traditional Mexican and Central American populations — did not develop pellagra despite corn-dominated diets.

When Europeans adopted corn from the Americas in the 16th century, they took the crop but not the nixtamalization technique. Italian polenta, Spanish gachas, and eventually southern US cornmeal were all prepared without alkali treatment. The result: a thousand-year nutritional accident that caused pellagra epidemics on three continents.

The lesson generalizes: traditional food preparation methods often carry crucial nutritional information that pure ingredient analysis misses. The chemistry of niacytin hydrolysis was not understood until the 1940s, but the Maya solved the problem empirically by 1500 BCE.

Back to Table of Contents

Joseph Goldberger's Epidemiologic Detective Work

Joseph Goldberger was a Hungarian-born physician working at the US Public Health Service when he was assigned in 1914 to investigate the southern pellagra epidemic. The dominant medical hypothesis was that pellagra was an infectious disease — spread by mold contamination of corn (the "Zeist theory") or by an unknown insect vector. Goldberger's epidemiologic observations rapidly demolished both hypotheses:

• Goldberger's institutional observations. In orphanages, mental hospitals, and prisons where pellagra raged among inmates, the staff who worked in the same buildings and breathed the same air did not get pellagra — but they ate from different kitchens. The staff diets included fresh meat, milk, and eggs. The inmate diets were primarily cornmeal and salt pork.
• The Mississippi orphanage experiment (1914-1915). Goldberger arranged to add fresh milk, eggs, meat, and legumes to the diet of two orphanages with high pellagra rates. Within months, active pellagra disappeared from both institutions.
• The Rankin Prison Farm experiment (1915). Goldberger persuaded the Mississippi governor to commute the sentences of 11 prison volunteers in exchange for being deliberately fed the "three M" pellagra diet (cornmeal, salt pork, molasses, no fresh foods). After 5-6 months, 6 of the 11 prisoners developed unmistakable clinical pellagra. The "controls" eating a normal mixed diet remained healthy. The experiment definitively proved pellagra was a dietary deficiency.
• The "filth parties" (1916). To refute the infection hypothesis, Goldberger, his wife, and colleagues deliberately ingested capsules containing scabs, urine, feces, and nasal secretions from active pellagra patients. None developed pellagra. The infectious hypothesis was untenable.
• The seven textile mill communities study (1916-1918). Goldberger documented that pellagra incidence in cotton-mill villages correlated with household economic stress (which determined diet quality), not with infection vectors. Higher income meant access to fresh meat and dairy and lower pellagra rates.

Despite this overwhelming evidence, Southern politicians, agricultural interests, and traditionalists in medicine resisted Goldberger's conclusions because they implicated rural poverty and the southern economy. Goldberger published the seven-mill study in Public Health Reports in 1923 and continued working on pellagra until his death from cancer in 1929 — eight years before Conrad Elvehjem and colleagues finally isolated and identified nicotinic acid as the missing factor (1937, University of Wisconsin), and 14 years before flour fortification with niacin became national policy in 1942.

Goldberger never knew exactly what was missing from the southern diet, but he knew with certainty that it was something in fresh meat, eggs, and milk — and he had the moral courage to deliberately ingest pellagra patient secretions to disprove the infection hypothesis when politics tried to shame him into silence. The story is a classic in scientific epidemiology and political courage.

Back to Table of Contents

The Four Ds — Dermatitis, Diarrhea, Dementia, Death

The mnemonic "the four Ds" captures the natural history of untreated pellagra:

1. Dermatitis — bilateral, symmetrical, photosensitive skin rash that begins as erythema on sun-exposed areas (face, neck, back of hands, dorsum of feet) and progresses through vesiculation, hyperpigmentation, thickening, scaling, and eventual cracking and ulceration. The rash is dramatic and pathognomonic. Casal's necklace (see next section) is the classic presentation.
2. Diarrhea — inflammation of the entire gastrointestinal (GI) tract: glossitis (smooth, painful, beefy-red tongue), angular stomatitis, esophagitis, gastritis, profuse watery diarrhea, and progressive malabsorption that worsens the underlying deficiency.
3. Dementia — progressive neurological and psychiatric deterioration: irritability, anxiety, insomnia, then depression and apathy, then confusion, disorientation, hallucinations, delusions, and full-blown psychosis. The "pellagra psychosis" historically filled southern asylums in the early 20th century. End-stage pellagra produces severe dementia indistinguishable from late Alzheimer's disease.
4. Death — without treatment, pellagra is fatal. Death typically follows from secondary infection in malnourished, immunocompromised patients with broken skin and severe malabsorption, or from cardiovascular collapse, or from accidents and suicide during the psychotic phase.

With niacin repletion, the symptoms reverse in a predictable order: psychiatric symptoms improve first (within 24-48 hours), then gastrointestinal symptoms (over 1-2 weeks), then dermatitis (over weeks to months, with hyperpigmentation sometimes persisting). If treatment is delayed until end-stage dementia is established, some neurological damage may be irreversible.

Back to Table of Contents

Casal's Necklace and the Pellagra Dermatitis Pattern

Gaspar Casal, the 18th-century Spanish physician who first described pellagra, drew careful clinical illustrations of a band-like dermatitis around the neck — the rash extends down across the upper chest in the V-shape of an open-collared shirt, sparing the covered skin. This collar-line dermatitis became known as Casal's necklace (collar of Casal) and remains a pathognomonic finding.

The pattern reflects photosensitive damage. The pellagra rash appears specifically where:

• Skin is exposed to sunlight (ultraviolet-B in particular)
• Niacin/nicotinamide adenine dinucleotide (NAD+) deficiency impairs the cellular DNA-repair response to ultraviolet (UV) damage
• The skin's barrier function (which depends on nicotinamide adenine dinucleotide-supported ceramide synthesis) is already compromised

Other classical pellagra dermatitis patterns:

• "Glove" pattern: sharply demarcated rash on the dorsum of the hands extending up to the wrist, sparing skin under long sleeves
• "Boot" pattern: similar pattern on the dorsum of the feet and ankles extending up to where socks or trouser cuffs covered the skin
• "Butterfly" pattern: across the bridge of the nose and cheeks (can resemble lupus malar rash, but pellagra extends to include the upper chest in Casal's necklace pattern, which lupus rarely does)
• "Goose foot" pattern (Patte d'oie): the rash on the back of the neck running into wrinkle lines

The bilateral symmetry and sharp demarcation along sun-exposure lines are highly characteristic. A photosensitive dermatitis in an alcoholic, a Crohn's patient, or anyone on isoniazid is a classic prompt for clinicians to consider pellagra.

Back to Table of Contents

Hidden Modern Pellagra — Alcoholism, Crohn's, Hartnup

Frank textbook pellagra is now rare in developed countries because of flour fortification with niacin (mandated in the US since 1942) and generally adequate protein intake. But hidden or subclinical pellagra still occurs and is frequently missed because clinicians no longer consider it.

Chronic alcoholism

The most common modern cause. Alcohol contributes multiple hits: (1) alcohol metabolism by alcohol dehydrogenase and aldehyde dehydrogenase consumes massive amounts of nicotinamide adenine dinucleotide in the liver, depleting hepatic stores; (2) chronic alcoholics frequently have poor diet quality with low protein and B-vitamin intake; (3) alcohol impairs intestinal absorption of multiple B vitamins; (4) alcoholic liver disease impairs the Preiss-Handler conversion of nicotinic acid to nicotinamide adenine dinucleotide. Alcoholics frequently present with partial pellagra — photosensitive dermatitis, glossitis, irritability, and confusion that's attributed to alcohol itself rather than to niacin deficiency. Broad B-complex replacement (including pellagra-level niacin doses) is standard practice in malnourished alcoholics.

Crohn's disease and Inflammatory Bowel Disease

Active small-bowel Crohn's disease causes malabsorption of all B vitamins. Chronic intestinal inflammation also induces IDO (indoleamine 2,3-dioxygenase) which diverts tryptophan away from nicotinamide adenine dinucleotide synthesis toward kynurenine pathway metabolites. The combination of malabsorption plus increased tryptophan catabolism can produce secondary pellagra in poorly nourished Crohn's patients. The warning combination in a Crohn's patient is photosensitive dermatitis together with worsening cognitive symptoms.

Hartnup disease

A rare autosomal recessive disorder caused by SLC6A19 gene mutations affecting the neutral amino acid transporter in the intestine and renal tubules. Patients cannot adequately absorb tryptophan from the gut or reabsorb it in the kidneys. Clinical presentation includes a pellagra-like photosensitive rash, episodic cerebellar ataxia, and psychiatric symptoms — usually presenting in childhood and triggered by sunlight exposure, fever, or stress. Treatment is high-dose nicotinamide (50-300 mg/day) plus a high-protein diet. Symptoms usually resolve completely with treatment though episodes can recur during stress.

Back to Table of Contents

Secondary Pellagra — Carcinoid, Isoniazid, Human Immunodeficiency Virus

Carcinoid syndrome

Serotonin-producing carcinoid tumors (originating from enterochromaffin cells, typically in the small intestine, appendix, or bronchus) divert up to 60% of dietary tryptophan into serotonin synthesis, depleting the substrate pool available for nicotinamide adenine dinucleotide biosynthesis. Pellagra is a classical late-stage carcinoid syndrome finding (alongside flushing, diarrhea, and right-sided valvular heart disease). Treatment requires both tumor control and high-dose niacin replacement.

Isoniazid (INH)

The tuberculosis drug isoniazid is a pyridoxine (B6) antagonist — it forms a covalent adduct with B6 and depletes the active cofactor. B6 is required for kynureninase in the de novo nicotinamide adenine dinucleotide synthesis pathway. INH-treated patients develop secondary pellagra-like symptoms (rash, neuropathy, psychiatric symptoms) that respond to combined B6 and niacin supplementation. Standard practice is to co-prescribe 25-50 mg/day pyridoxine with any isoniazid regimen.

Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome

Chronic human immunodeficiency virus (HIV) infection induces sustained IDO expression in macrophages and dendritic cells, dramatically increasing tryptophan catabolism into the kynurenine pathway — producing neurotoxic quinolinic acid and depleting the substrate available for serotonin synthesis. The clinical manifestation includes pellagra-like dermatitis, neuropsychiatric symptoms (human immunodeficiency virus-associated dementia), and depression. Niacin supplementation helps but does not fully reverse the underlying tryptophan diversion.

Other causes

• Anorexia nervosa and severe protein-calorie malnutrition
• Bariatric surgery (especially gastric bypass — reduced absorption surface)
• Prolonged parenteral nutrition without adequate niacin
• Drug-induced: 5-fluorouracil, 6-mercaptopurine, chloramphenicol
• Tryptophan-poor diets in some extreme vegan patterns without adequate planning

Back to Table of Contents

Topical Niacinamide for Acne and Barrier Function

Topical nicotinamide (niacinamide) has become one of the most widely used active ingredients in modern dermatology, supported by substantial clinical trial evidence:

Acne vulgaris

• 4% topical niacinamide gel has been compared head-to-head with 1% clindamycin gel. In a 1995 double-blind trial, 76 people with moderate inflammatory acne applied one gel or the other twice daily for 8 weeks: 82% on nicotinamide and 68% on clindamycin were improved on the physician's global rating (P=0.19), and papules and pustules fell by 60% versus 43% (P=0.168) — statistically similar results. Nicotinamide does not contribute to antibiotic resistance and does not disrupt the skin microbiome the way topical antibiotics do.
• Mechanisms include inhibition of inflammatory cytokine release (interleukin-1, IL-8, tumor necrosis factor-α), suppression of leukocyte chemotaxis to lesions, and reduction of sebum production.
• Niacinamide is particularly useful in inflammatory adult acne and rosacea where antibiotic stewardship is a concern.

Skin barrier function

• Niacinamide upregulates the synthesis of ceramides (especially ceramide 3), free fatty acids, and cholesterol — the three lipid components of the stratum corneum lamellae that constitute the skin barrier.
• Topical 2-5% niacinamide reduces transepidermal water loss (TEWL), improves stratum corneum hydration, and helps repair barrier function in atopic dermatitis, rosacea, and post-procedure skin.
• The mechanism is partly nicotinamide adenine dinucleotide-dependent — ceramide synthesis requires sphingolipid pathway enzymes that depend on NAD/NADP cofactors.

Rosacea

Topical niacinamide 2% significantly reduces erythema and improves barrier function in rosacea, sometimes used as a steroid-sparing alternative or adjunct to azelaic acid and metronidazole.

Atopic dermatitis

Niacinamide in emollients reduces flare frequency and improves barrier function in pediatric and adult atopic dermatitis, often allowing reduced topical steroid use.

Back to Table of Contents

Niacinamide for Hyperpigmentation

Niacinamide reduces hyperpigmentation (melasma, post-inflammatory hyperpigmentation, age spots) through a mechanism distinct from hydroquinone or arbutin:

• Niacinamide does NOT inhibit tyrosinase (the rate-limiting enzyme of melanin synthesis) — melanin production itself is unaffected.
• Instead, niacinamide inhibits the transfer of melanosomes (pigment-containing organelles) from melanocytes to surrounding keratinocytes. The keratinocyte receives less pigment cargo.
• The effect is reversible and gentler than tyrosinase inhibitors — less risk of paradoxical post-inflammatory hyperpigmentation, no risk of exogenous ochronosis (which can occur with hydroquinone).

Topical niacinamide 4-5% over 8-12 weeks produces measurable reductions in melasma and post-inflammatory hyperpigmentation in clinical trials — not as dramatic as hydroquinone but with a much safer long-term profile, and effective in combination with sunscreen and azelaic acid in melasma protocols.

The melanosome-transfer finding comes from Greatens and colleagues (2005). In laboratory co-cultures of pigment cells and skin cells, niacinamide blocked melanosome transfer without harming the cells, and transfer resumed within 3 days after it was removed. In the same paper, a vehicle-controlled split-face trial found that topical niacinamide reduced facial hyperpigmented spots in a dose-dependent, reversible way. What is not known from this source: that trial measured facial spots, not melasma, so the melasma figures above are not tied to a trial cited on this page.

Back to Table of Contents

The ONTRAC Trial — Skin Cancer Chemoprevention

The ONTRAC trial (Oral Nicotinamide to Reduce Actinic Cancer), published by Chen et al. in the New England Journal of Medicine in 2015, is the landmark study establishing oral nicotinamide as evidence-based skin cancer chemoprevention.

Design

• 386 patients in Australia who had had at least two non-melanoma skin cancers (basal cell or squamous cell carcinoma) in the previous 5 years — a high-risk population
• Randomized to nicotinamide 500 mg twice daily or placebo
• 12 months of treatment
• Primary endpoint: number of new non-melanoma skin cancers

Results

• 23% reduction in new non-melanoma skin cancers (rate ratio 0.77, p = 0.02)
• 20% fewer new basal-cell carcinomas (BCC) (95% CI −6 to 39; P=0.12, not statistically significant) and 30% fewer new squamous-cell carcinomas (SCC) (95% CI 0 to 51; P=0.05)
• Actinic keratoses (precancerous lesions) were 11% fewer at 3 months, 14% fewer at 6 months, 20% fewer at 9 months, and 13% fewer at 12 months
• No noteworthy differences between the groups in the number or types of adverse events
• There was no evidence of benefit in the 6 months after nicotinamide was stopped, indicating continuous use is required

Mechanism

Ultraviolet radiation damages DNA via thymine dimer formation, depletes cellular nicotinamide adenine dinucleotide as poly(ADP-ribose) polymerases (PARPs) are activated to repair the damage, and suppresses local immune surveillance (the "ultraviolet immunosuppression" that allows precancerous cells to escape destruction). Nicotinamide:

• Replenishes cellular nicotinamide adenine dinucleotide, supporting continued PARP-mediated DNA repair after ultraviolet damage
• Provides energy for the adenosine triphosphate-dependent nucleotide excision repair pathway that removes thymine dimers
• Prevents ultraviolet-induced immunosuppression, allowing the immune system to clear damaged cells

Clinical implications

Many dermatologists use oral nicotinamide 500 mg twice daily for people at high risk of non-melanoma skin cancer — particularly fair-skinned people with extensive sun damage (actinic damage) and people with several prior basal-cell or squamous-cell carcinomas. In organ-transplant recipients on immune-suppressing drugs, however, the ONTRANS trial below found no benefit. The dose is well-tolerated, cheap (a few dollars per month), and the only common side effect is mild headache during the first week. Sustained use is required for sustained benefit.

Later studies: transplant recipients and a veterans' cohort

• ONTRANS (2023). The same Australian group gave 500 mg nicotinamide or placebo twice daily for 12 months to 158 organ-transplant recipients taking immune-suppressing drugs who had had at least two keratinocyte (basal-cell or squamous-cell) skin cancers in the past 5 years. There were 207 new skin cancers in the nicotinamide group and 210 in the placebo group (rate ratio 1.0, 95% CI 0.8–1.3, P=0.96), with no difference in actinic keratoses either. The trial stopped early because of poor recruitment.
• US veterans' record study (2025). An observational study of Veterans Affairs health records matched 12,287 people who took nicotinamide 500 mg twice daily for more than 30 days with 21,479 who did not. Skin-cancer risk was 14% lower overall and 54% lower when nicotinamide was started after a first skin cancer (the benefit shrank when it was started after later ones), with the largest drop for squamous-cell carcinoma. Among transplant recipients there was no overall significant reduction. This is a record study, not a randomized trial.

Back to Table of Contents

Niacinamide as a Skincare Ingredient (5-10%)

Niacinamide has become a workhorse ingredient in modern skincare formulations, appearing in serums, moisturizers, sunscreens, and treatment products from drugstore through luxury brands:

• 2-5% concentration is the typical "general purpose" range — barrier support, mild brightening, anti-inflammatory effects, suitable for daily use including sensitive skin
• 5-10% concentration is the "active treatment" range — more pronounced effects on hyperpigmentation, acne, and pore size; some users experience mild irritation at this level requiring gradual introduction
• Above 10% rarely adds benefit and increases irritation risk; well-formulated 10% products at appropriate pH (slightly acidic) are usually the practical ceiling

Formulation considerations

• Stability: niacinamide is stable in a wide pH range and tolerates most other actives well. Unlike vitamin C, it does not require special anti-oxidant packaging.
• Combining with vitamin C: the old concern that niacinamide and ascorbic acid form niacin (the flush-causing form) only matters at very high temperatures and concentrations. At skincare-product concentrations and skin temperature, they are compatible. Modern dermatology generally considers them safe to use together or in sequence.
• Combining with retinoids: niacinamide reduces retinoid-induced barrier disruption and irritation, making it an excellent buffer ingredient in retinol/tretinoin routines.
• Combining with alpha-hydroxy acids and salicylic acid: generally well-tolerated; users who get irritation often separate them by time of day (acids morning, niacinamide evening).

Back to Table of Contents

How Pellagra Is Treated

Treatment of confirmed or strongly suspected pellagra (history, clinical picture, response to treatment) typically includes:

Acute phase

• Nicotinamide 300-500 mg/day in 3 divided doses (nicotinamide rather than nicotinic acid, because it does not cause the flush — which matters in an already-distressed patient; in severe cases injectable nicotinamide can be used)
• A complete B-complex given alongside, including B1 (thiamine, 100 mg/day — critical in alcoholics, and given before any carbohydrate refeeding to prevent Wernicke's encephalopathy), B2, B6, B12, folate
• Protein-rich diet as tolerated to provide tryptophan substrate (eggs, dairy, meat if available)
• Treating the underlying cause: alcohol cessation, Crohn's disease management, isoniazid co-prescription of B6, carcinoid tumor workup, etc.

Expected response

• 24-48 hours: psychiatric symptoms begin to improve — reduced confusion, better orientation, calmer affect
• 3-7 days: gastrointestinal symptoms (diarrhea, glossitis) improve substantially
• Weeks to months: dermatitis resolves; hyperpigmentation may persist longer
• No improvement in 1 week: a reason to reconsider the diagnosis or look for ongoing causative factors

Maintenance and prevention

• Long-term nicotinamide 100-300 mg/day plus B-complex in patients with permanent risk factors (chronic alcoholism, inflammatory bowel disease (IBD), Hartnup disease, carcinoid syndrome, chronic isoniazid therapy)
• Sustained dietary improvement and protein adequacy
• Addressing the root cause (sobriety, inflammatory bowel disease remission, etc.), which allows eventual discontinuation when safe

For Hartnup disease specifically, lifelong nicotinamide 50-300 mg/day (titrated to symptom control) plus a high-protein diet is the standard approach. Most patients have a normal life expectancy with treatment.

Back to Table of Contents

Cautions

• HEPATOTOXICITY — sustained-release nicotinic acid at >1 g/day. Sustained-release (SR) nicotinic acid at gram-range doses carries this liver risk even in pellagra treatment. Immediate-release nicotinic acid carries less, and nicotinamide does not cause flushing and has minimal hepatotoxicity at typical doses.
• Wernicke's encephalopathy precaution in alcoholics. Standard practice is thiamine 100 mg intravenous (IV) or intramuscular (IM) BEFORE any glucose, carbohydrate refeeding, or even niacin in a malnourished alcoholic. Thiamine-deficient brain tissue can develop irreversible Wernicke's encephalopathy when carbohydrate metabolism is suddenly resumed without B1.
• Carcinoid syndrome work-up first. Unexplained pellagra in an adult without alcohol or malabsorption raises the question of carcinoid syndrome; the tests used are serum chromogranin A and 24-hour urinary 5-hydroxyindoleacetic acid (5-HIAA). Niacin replacement is necessary but doesn't address the underlying tumor.
• Sustained nicotinamide > 3 g/day. Chronic very-high-dose nicotinamide can cause sirtuin product inhibition and theoretical hepatotoxicity. Practitioners commonly keep routine nicotinamide use at or below 2 g/day, with higher doses kept for short-term pellagra treatment under monitoring.
• Topical niacinamide irritation. At concentrations > 5% some users experience mild stinging, redness, or flushing-like erythema (separate from the GPR109A flush of oral nicotinic acid). Users commonly introduce it gradually, or move to a lower concentration when irritation persists.
• Drug interactions: isoniazid (B6 is co-prescribed, as noted); 5-fluorouracil and other chemotherapy (5-fluorouracil itself can cause pellagra, as listed above, and high-dose nicotinamide with chemotherapy is not well studied); levodopa (modest interaction).
• Diagnostic ambiguity. Photosensitive dermatitis in the modern era is more often lupus, drug photosensitivity, or porphyria than pellagra. A skin biopsy may be needed; an empirical trial of niacin replacement is often diagnostic if response is dramatic.

Back to Table of Contents

Key Research Papers

1. Goldberger J et al. (1923). A study of the relation of diet to pellagra incidence in seven textile-mill communities of South Carolina. Public Health Reports. — PubMed
2. Goldberger J, Wheeler GA (1915). Experimental pellagra in the human subject brought about by a restricted diet. Public Health Reports; reprinted in Nutrition 1990;6(5):357-60. — PubMed PMID: 2134557
3. Elvehjem CA et al. (1937). Relation of nicotinic acid and nicotinic acid amide to canine black tongue. J Am Chem Soc. — PubMed
4. Chen AC et al. (2015). A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention (ONTRAC). NEJM. — PubMed PMID: 26488693
5. Allen NC, Martin AJ, Snaidr VA, et al. (2023). Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients (ONTRANS). N Engl J Med 388(9):804-812. — PubMed PMID: 36856616
6. Breglio KF, Knox KM, Hwang J, et al. (2025). Nicotinamide for Skin Cancer Chemoprevention. JAMA Dermatol 161(11):1140-1147. — PubMed PMID: 40960808
7. Hegyi J et al. (2004). Pellagra: dermatitis, dementia, and diarrhea. Int J Dermatol. — PubMed PMID: 14693013
8. Kravetz Z, Schmidt-Kastner R (2023). New aspects for the brain in Hartnup disease based on mining of high-resolution cellular mRNA expression data for SLC6A19. IBRO Neurosci Rep 14:393-397. — PubMed PMID: 37101820
9. Shalita AR, Smith JG, Parish LC, Sofman MS, Chalker DK (1995). Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. Int J Dermatol 34(6):434-7. — PubMed PMID: 7657446
10. Niacinamide and ceramide synthesis / barrier function — PubMed
11. Greatens A, Hakozaki T, Koshoffer A, et al. (2005). Effective inhibition of melanosome transfer to keratinocytes by lectins and niacinamide is reversible. Exp Dermatol 14(7):498-508. — PubMed PMID: 15946237
12. Crohn's disease and secondary pellagra — PubMed PMID: 33039468
13. Alcoholism and pellagra — PubMed
14. Carcinoid syndrome and tryptophan diversion / pellagra — PubMed
15. Isoniazid-induced pellagra — PubMed PMID: 91851

PubMed Topic Searches

1. PubMed: pellagra niacin deficiency
2. PubMed: topical niacinamide dermatology
3. PubMed: nicotinamide chemoprevention
4. PubMed: nixtamalization niacin
5. PubMed: Hartnup disease

Back to Table of Contents

Connections

• All Vitamins
• Vitamin B3 Overview
• B3 Benefits Hub
• B3 as Nicotinamide Adenine Dinucleotide Precursor
• B3 for Cholesterol & Cardiovascular
• B3 for Schizophrenia & Mental Health
• Pellagra & Niacin Deficiency (Original Article)
• Tryptophan
• Niacin in Gerson Therapy
• Schizophrenia
• Dementia
• Vitamin B1 (Thiamine)
• Vitamin B6 (Pyridoxine)
• Vitamin B2 (Riboflavin)
• Nicotinamide Adenine Dinucleotide / Nicotinamide Mononucleotide
• Deficiency
• Toxicity
• History
• Sources

Back to Table of Contents

Featured Videos

×